Fulcrum Therapeutics (FULC) Current Deferred Revenue (2019 - 2023)

Fulcrum Therapeutics (FULC) has 5 years of Current Deferred Revenue data on file, last reported at $600000.0 in Q3 2023.

• On a quarterly basis, Current Deferred Revenue rose 50.0% year-over-year to $600000.0 in Q3 2023; TTM through Sep 2023 was $600000.0, a 50.0% increase from a year earlier, with the FY2022 full-year figure at $900000.0, down 71.88% from the prior year.
• Current Deferred Revenue for Q3 2023 stood at $600000.0, up from $513000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for FULC reached as high as $14.9 million in Q4 2020 and fell as low as $400000.0 in Q3 2022.
• Historically, Current Deferred Revenue has averaged $4.1 million across 5 years, with a median of $2.0 million in 2021.
• Across the five-year window, Current Deferred Revenue surged 273.78% in 2020 and tumbled 89.28% in 2022, its largest moves.
• Year by year, Current Deferred Revenue stood at $4.0 million in 2019, then jumped by 273.78% to $14.9 million in 2020, then plunged by 78.54% to $3.2 million in 2021, then plunged by 71.88% to $900000.0 in 2022, then plunged by 33.33% to $600000.0 in 2023.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $600000.0 in Q3 2023, $513000.0 in Q2 2023, and $737000.0 in Q1 2023.